Advanced Breast Carcinoma, Advanced Ovarian Carcinoma
Conditions
Keywords
Advanced breast carcinoma, Advanced ovarian carcinoma, MUC1, vaccine, Phase 1b
Brief summary
This is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10. Intermediate and/or lower doses of varlilumab or ONT-10 may also be studied at the recommendation of the safety monitoring committee (SMC).
Detailed description
This is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10. Intermediate and/or lower doses of varlilumab or ONT-10 may also be studied at the recommendation of the safety monitoring committee (SMC). Treatment will be administered in cycles of 12 weeks each. All patients will receive a single dose of cyclophosphamide on Day -3. During Cycle 1, patients will receive ONT-10 administered SC once per week for 8 weeks followed by ONT-10 once every 6 weeks starting with Cycle 2, in combination with varlilumab administered IV once every 3 weeks x 3 doses, and then once every 6 weeks for cycles 2 through 5. Each cohort will enroll an initial group of 6 evaluable patients with either breast or ovarian carcinoma. Initial enrollment into a cohort will be staggered, with the first patient treated in any new cohort to be followed for a minimum of two weeks for the occurrence of Unacceptable Toxicity prior to enrollment of the remaining 5 patients. Subsequent enrollment into a cohort may then continue without a staggered schedule until 6 patients treated are considered evaluable. Up to 24 additional evaluable patients may be enrolled and treated in Part 2 at the RD of varlilumab and ONT-10 identified in Part 1, including approximately equal numbers of patients with breast carcinoma (n\ 12) and ovarian carcinoma (n\ 12). Treatment in Part 2 will follow the same schedule as in Part 1.
Interventions
BIOLOGICALONT-10, Varlilumab combination
ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant. Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27.
Sponsors
Celldex Therapeutics
Cascadian Therapeutics Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Be at least 18 years of age at the time of consent 2. Life expectancy of at least 6 months, in the opinion of the investigator 3. Have histologically confirmed breast or ovarian carcinoma 4. Have evidence of persistent, recurrent, or progressive disease for which there is no known or established treatment available with curative intent, after at least one course of systemic therapy for locally advanced or metastatic disease , including chemotherapy, targeted therapy (small molecule or antibody based), or hormonal therapy 5. Measurable or evaluable disease by RECIST 1.1 6. ECOG performed status of 0 or 1 7. Adequate hematologic function defined by: 8. WBC count ≥ 3.0 x 103 cells/µL 9. Lymphocyte count ≥ 0.8 x 103 cells/µL 10. Platelet count ≥ 75 x 103 /µL, and 11. Hemoglobin ≥ 9 g/dL 12. Have renal and hepatic function as defined by: 13. AST and ALT ≤ 2.5 X ULN 14. Total bilirubin ≤ 1.5 X ULN. Patients with elevated bilirubin known to be due to Gilbert's disease may be enrolled after approval from the medical monitor, and 15. Creatinine clearance ≥ 50 mL/min 16. If female of child bearing potential, have a negative pregnancy test at screening 17. If fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device, abstinence or other methods prescribed by a licensed healthcare provider) from the time of consent through 70 days following the last dose of study drug 18. Patient or a legally authorized representative of a patient must be able and willing to sign informed consent document that has been approved by an IRB
Exclusion criteria
1. Has medical, social, or psychological factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures 2. Is pregnant, breastfeeding, or planning a pregnancy 3. Has received treatment with any systemic anticancer therapy, wide-field radiation, or experimental agent within 4 weeks of receiving cyclophosphamide on Day -3, with the exception of anticancer hormonal therapy, which may not be given within 2 weeks of receiving cyclophosphamide on Day -3. All residual toxicity related to prior anticancer therapies (excluding vitiligo, endocrinopathies on stable replacement therapy, alopecia and Grade 2 fatigue) must resolve to Grade 1 severity or less or return to baseline prior to receipt of study treatment. 4. Has received treatment with focal radiotherapy within 2 weeks, or radiopharmaceuticals (e.g., strontium, samarium) within 8 weeks of receiving cyclophosphamide on Day -3 5. Has untreated or uncontrolled CNS metastases, including patients who require glucocorticoid therapy for CNS metastases 6. Has received prior treatment with ONT-10 or varlilumab, or prior treatment with other MUC1 vaccines or CD27-targeted agents 7. Has active autoimmune disease or a documented history of autoimmune disease, or history of potential autoimmune syndrome that required systemic steroids or immunosuppressive medications, except for patients with vitiligo, endocrinopathies, type 1 diabetes, or patients with resolved childhood asthma/atopy or other syndromes which would not be expected to recur in the absence of an external trigger (e.g., drug-related serum sickness or post-streptococcal glomerulonephritis). Patients with mild asthma who require intermittent use of bronchodilators (such as albuterol) who have not been hospitalized for asthma in the preceding 3 years will not be excluded from this study. 8. Has recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia, and/or other hereditary congenital immunodeficiencies 9. Has any pre-existing medical condition requiring systemic chronic steroid or immunosuppressive therapy a) Inhaled corticosteroids for COPD or topical steroids are allowed 10. Known to be positive for HIV, or to have active hepatitis B, or hepatitis C, or have active infection of any kind requiring systemic therapy 11. Administration of any other vaccine ≤ 4 weeks of receiving cyclophosphamide on Day -3 12. Underlying medical condition that, in the Investigator's opinion, will make the administration of study treatment hazardous or obscure the interpretation of toxicity determination of adverse events. This includes other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancer; or any other cancer from which the patient has been disease-free for at least 3 years. 13. Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension (persistent systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications) or arrhythmia, congestive heart failure (NYHA Class III or IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or myocardial infarction within 6 months prior to the first dose of study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events as a measure of safety and tolerability | Cycles of 12 weeks | Assessment of the adverse event profile as an indication of overall safety and tolerability of the combination treatment with ONT-10 and varlilumab |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immune Response to MUC1 | 8 weeks on a weekly basis, followed by every 6 weeks | Determine the immune response of the drug combination of varlilumab and ONT-10 to MUC1 specific humoral and cellular responses. |
Countries
United States
Outcome results
None listed